Virginia Olivia Volpe, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 5 | 2023 | 1399 | 1.360 |
Why?
|
| Neutropenia | 1 | 2023 | 892 | 0.570 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1061 | 0.570 |
Why?
|
| SEER Program | 1 | 2021 | 1444 | 0.520 |
Why?
|
| Anemia | 1 | 2023 | 1514 | 0.420 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 3626 | 0.330 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1594 | 0.300 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2024 | 1642 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2024 | 370 | 0.210 |
Why?
|
| Phosphoproteins | 2 | 2022 | 2450 | 0.210 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 24 | 0.210 |
Why?
|
| Mutation | 7 | 2024 | 30211 | 0.210 |
Why?
|
| Ribosomal Proteins | 1 | 2024 | 369 | 0.200 |
Why?
|
| Primary Myelofibrosis | 1 | 2024 | 209 | 0.190 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 93 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5694 | 0.180 |
Why?
|
| Chromosome Deletion | 1 | 2024 | 1384 | 0.160 |
Why?
|
| Prognosis | 8 | 2024 | 29979 | 0.160 |
Why?
|
| Melanoma | 1 | 2017 | 5706 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 5861 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.130 |
Why?
|
| Azetidines | 1 | 2017 | 152 | 0.130 |
Why?
|
| Oximes | 1 | 2017 | 303 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2017 | 386 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13658 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1777 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2017 | 863 | 0.100 |
Why?
|
| Pyridones | 1 | 2017 | 819 | 0.100 |
Why?
|
| Imidazoles | 1 | 2017 | 1168 | 0.090 |
Why?
|
| Survival Rate | 2 | 2021 | 12828 | 0.090 |
Why?
|
| Disease Progression | 3 | 2022 | 13665 | 0.090 |
Why?
|
| Indoles | 1 | 2017 | 1835 | 0.080 |
Why?
|
| Piperidines | 1 | 2017 | 1667 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11873 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2017 | 1982 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 2058 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2824 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2022 | 12165 | 0.050 |
Why?
|
| Aged | 7 | 2024 | 171446 | 0.050 |
Why?
|
| Humans | 11 | 2024 | 767991 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2022 | 258 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2024 | 561 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2022 | 657 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 9252 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2021 | 10098 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 59598 | 0.030 |
Why?
|
| Risk Factors | 1 | 2023 | 74936 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2019 | 1609 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 1601 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 3669 | 0.020 |
Why?
|
| Middle Aged | 5 | 2024 | 223422 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 4833 | 0.020 |
Why?
|
| Male | 6 | 2024 | 364641 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 3409 | 0.020 |
Why?
|
| Female | 6 | 2024 | 397113 | 0.020 |
Why?
|
| Adult | 4 | 2024 | 223583 | 0.020 |
Why?
|
| Comorbidity | 1 | 2019 | 10590 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2024 | 81746 | 0.010 |
Why?
|
| Young Adult | 2 | 2021 | 60048 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5717 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39345 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 41749 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24314 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2024 | 65364 | 0.010 |
Why?
|